1
|
Tiran AL, Claperon A, Davidson J, Starck JB, Diguarher TL, Chanrion M, Mistry P, Wang Y, Monceau E, Bernhardt F, Rocchetti F, Lysiak-Auvity G, Chen I, Daniels Z, Pedder C, Fallowfield M, Henlin JM, Fejes I, Tatai J, Nyerges M, Durand D, Zarka M, Sanghavi S, Girard AM, Schoumacher M, Kraus-Berthier L, Newcombe R, Halilovic E, Banquet S, Rupin A, Maacke H, Murray J, Morris E, Hofmann F, Colland F, Geneste O. Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Venetoclax (Venclexta™), a selective BCL-2 inhibitor, is the first member of a new class of anti-cancer drugs, called BH3 mimetics, to be approved for CLL and AML. Here, we describe the identification of a novel potent and selective BCL-2 inhibitor named S65487/VOB560 that has a different binding mode on BCL-2 compared to Venetoclax. This inhibitor binds to the BH3 hydrophobic groove of BCL-2. Its selectivity profile demonstrates lack of significant binding to MCL-1, BFL-1 and poor affinity for BCL-XL. S65487/VOB560 induces apoptosis in a panel of hematological cancer cell lines and inhibits cell proliferation with IC50s in the low nM range. S65487/VOB560 induces complete regression in BCL-2-dependent RS4;11 tumors in vivo after a single IV (intravenous) administration. Strong and persistent tumor regression in xenograft models of lymphoid malignancies in mouse and rat were observed at well tolerated doses following weekly IV administration of S65487 in combination with the MCL-1-specific inhibitor, S64315/MIK665. These positive findings were further confirmed in a panel of AML PDX tumor models. Recently, acquired BCL-2 mutations (such as G101V and D103Y) were identified in patients with Chronic Lymphocytic Leukemia becoming resistant to Venetoclax. Interestingly, S65487/VOB560 is active on such BCL-2 mutants and induces apoptosis in preclinical resistance models. Altogether, these data demonstrate that S65487/VOB560 has significant therapeutic potential against human lymphoid and myeloid malignancies as well as in patients with Venetoclax resistant leukemias. Clinical studies are currently ongoing with S65487/VOB560 (NCT03755154).
Citation Format: Arnaud Le Tiran, Audrey Claperon, James Davidson, Jérôme-Benoit Starck, Thierry Le Diguarher, Maïa Chanrion, Prakash Mistry, Youzhen Wang, Elodie Monceau, Fabienne Bernhardt, Francesca Rocchetti, Gaelle Lysiak-Auvity, Ijen Chen, Zoe Daniels, Chris Pedder, Mandy Fallowfield, Jean-Michel Henlin, Imre Fejes, Janos Tatai, Miklos Nyerges, Didier Durand, Marion Zarka, Sneha Sanghavi, Anne-Marie Girard, Marie Schoumacher, Laurence Kraus-Berthier, Rick Newcombe, Ensar Halilovic, Sébastien Banquet, Alain Rupin, Heiko Maacke, James Murray, Erick Morris, Francesco Hofmann, Frédéric Colland, Olivier Geneste. Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1276.
Collapse
Affiliation(s)
- Arnaud Le Tiran
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Audrey Claperon
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | | | - Jérôme-Benoit Starck
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Thierry Le Diguarher
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Maïa Chanrion
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Prakash Mistry
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | - Youzhen Wang
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Elodie Monceau
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Fabienne Bernhardt
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Francesca Rocchetti
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | | | - Ijen Chen
- 3Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | - Zoe Daniels
- 3Vernalis (R&D) Ltd, Cambridge, United Kingdom
| | | | | | - Jean-Michel Henlin
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Imre Fejes
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Janos Tatai
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Miklos Nyerges
- 6Servier Research Institute of Medicinal Chemistry, Budapest, Hungary
| | - Didier Durand
- 1Institut de Recherches Servier Discovery Chemistry Unit, Croissy-sur-Seine, France
| | - Marion Zarka
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Sneha Sanghavi
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Anne-Marie Girard
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Marie Schoumacher
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | | | - Rick Newcombe
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Ensar Halilovic
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Sébastien Banquet
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Alain Rupin
- 7Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France
| | - Heiko Maacke
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | | | - Erick Morris
- 5Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA
| | - Francesco Hofmann
- 4Novartis Institute of Biomedical Research, Oncology Drug Discovery, Basel, Switzerland
| | - Frédéric Colland
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| | - Olivier Geneste
- 2Institut de Recherches Servier Oncology R&D Unit, Croissy-sur-Seine, France
| |
Collapse
|
2
|
Collier PN, Panchagnula A, O’Dowd H, Le Tiran A, Aronov AM. Synthesis of a 6-Aza-Isoindolinone-Based Inhibitor of Phosphoinositide 3-Kinase γ via Ruthenium-Catalyzed [2 + 2 + 2] Cyclotrimerization. ACS Med Chem Lett 2019; 10:117-120. [PMID: 30655957 DOI: 10.1021/acsmedchemlett.8b00530] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2018] [Accepted: 11/29/2018] [Indexed: 12/18/2022] Open
Abstract
Phosphoinositide 3-kinase (PI3Kγ) is a drug target that has been implicated in the treatment of a range of diseases. We have developed a synthesis of a novel PI3Kγ inhibitor containing a 1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one scaffold. The key step in the synthesis involved a ruthenium-catalyzed [2 + 2 + 2] cyclotrimerization reaction between a diyne and an alkoxycarbonyl isocyanate, a previously unreported coupling partner in such a reaction.
Collapse
Affiliation(s)
- Philip N. Collier
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Advaita Panchagnula
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Hardwin O’Dowd
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Arnaud Le Tiran
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Alex M. Aronov
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| |
Collapse
|
3
|
Maertens G, Saavedra OM, Vece V, Reyes MAV, Hocine S, Öney E, Goument B, Mirguet O, Le Tiran A, Gloanec P, Hanessian S. Design and synthesis of bridged piperidine and piperazine isosteres. Bioorg Med Chem Lett 2018; 28:2627-2630. [PMID: 29937060 DOI: 10.1016/j.bmcl.2018.06.038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Accepted: 06/17/2018] [Indexed: 01/11/2023]
Abstract
We have developed versatile methods toward the synthesis of a variety of piperidine/piperazine bridged isosteres of pridopidine. The compounds were assessed against the D2 receptor in agonist and antagonist modes and against the D4 receptor in agonist mode. hERG Binding and the ADME profiles were studied.
Collapse
Affiliation(s)
- Gaëtan Maertens
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Oscar M Saavedra
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Vito Vece
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Miguel A Vilchis Reyes
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Sofiane Hocine
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Esat Öney
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada
| | - Bertrand Goument
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Olivier Mirguet
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Arnaud Le Tiran
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Philippe Gloanec
- Institut de Recherches Servier, 11 rue des Moulineaux, 92150 Suresnes, France
| | - Stephen Hanessian
- Department of Chemistry, Université de Montréal, Station Centre-Ville, C.P. 6128 Montréal, QC H3C 3J7, Canada.
| |
Collapse
|
4
|
Come JH, Collier PN, Henderson JA, Pierce AC, Davies RJ, Le Tiran A, O'Dowd H, Bandarage UK, Cao J, Deininger D, Grey R, Krueger EB, Lowe DB, Liang J, Liao Y, Messersmith D, Nanthakumar S, Sizensky E, Wang J, Xu J, Chin EY, Damagnez V, Doran JD, Dworakowski W, Griffith JP, Jacobs MD, Khare-Pandit S, Mahajan S, Moody CS, Aronov AM. Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS). J Med Chem 2018; 61:5245-5256. [PMID: 29847724 DOI: 10.1021/acs.jmedchem.8b00085] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The lipid kinase phosphoinositide 3-kinase γ (PI3Kγ) has attracted attention as a potential target to treat a variety of autoimmune disorders, including multiple sclerosis, due to its role in immune modulation and microglial activation. By minimizing the number of hydrogen bond donors while targeting a previously uncovered selectivity pocket adjacent to the ATP binding site of PI3Kγ, we discovered a series of azaisoindolinones as selective, brain penetrant inhibitors of PI3Kγ. This ultimately led to the discovery of 16, an orally bioavailable compound that showed efficacy in murine experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis.
Collapse
Affiliation(s)
- Jon H Come
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Philip N Collier
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - James A Henderson
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Albert C Pierce
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Robert J Davies
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Arnaud Le Tiran
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Hardwin O'Dowd
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Upul K Bandarage
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Jingrong Cao
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - David Deininger
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Ron Grey
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Elaine B Krueger
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Derek B Lowe
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Jianglin Liang
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Yusheng Liao
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - David Messersmith
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Suganthi Nanthakumar
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Emmanuelle Sizensky
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Jian Wang
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Jinwang Xu
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Elaine Y Chin
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Veronique Damagnez
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - John D Doran
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Wojciech Dworakowski
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - James P Griffith
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Marc D Jacobs
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Suvarna Khare-Pandit
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Sudipta Mahajan
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Cameron S Moody
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| | - Alex M Aronov
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue , Boston , Massachusetts 02210 , United States
| |
Collapse
|
5
|
O’Dowd H, Shannon DE, Chandupatla KR, Dixit V, Engtrakul JJ, Ye Z, Jones SM, O’Brien CF, Nicolau DP, Tessier PR, Crandon JL, Song B, Macikenas D, Hanzelka BL, Le Tiran A, Bennani YL, Charifson PS, Grillot AL. Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. ACS Med Chem Lett 2015; 6:822-6. [PMID: 26191374 DOI: 10.1021/acsmedchemlett.5b00196] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 06/22/2015] [Indexed: 11/29/2022] Open
Abstract
Benzimidazole 1 is the lead compound resulting from an antibacterial program targeting dual inhibitors of bacterial DNA gyrase and topoisomerase IV. With the goal of improving key drug-like properties, namely, the solubility and the formulability of 1, an effort to identify prodrugs was undertaken. This has led to the discovery of a phosphate ester prodrug 2. This prodrug is rapidly cleaved to the parent drug molecule upon both oral and intravenous administration. The prodrug achieved equivalent exposure of 1 compared to dosing the parent in multiple species. The prodrug 2 has improved aqueous solubility, simplifying both intravenous and oral formulation.
Collapse
Affiliation(s)
- Hardwin O’Dowd
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Dean E. Shannon
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Kishan R. Chandupatla
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Vaishali Dixit
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Juntyma J. Engtrakul
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Zhengqi Ye
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Steven M. Jones
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Colleen F. O’Brien
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - David P. Nicolau
- Center
for Anti-Infective Research and Development, Hartford Hospital, 80
Seymour Street, Hartford, Connecticut 06102, United States
| | - Pamela R. Tessier
- Center
for Anti-Infective Research and Development, Hartford Hospital, 80
Seymour Street, Hartford, Connecticut 06102, United States
| | - Jared L. Crandon
- Center
for Anti-Infective Research and Development, Hartford Hospital, 80
Seymour Street, Hartford, Connecticut 06102, United States
| | - Bin Song
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Dainius Macikenas
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Brian L. Hanzelka
- Vertex Pharmaceuticals Incorporated, 2500 Crosspark Road, Bioventures Center, Coralville, Iowa 52241, United States
| | - Arnaud Le Tiran
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Youssef L. Bennani
- Vertex Pharmaceuticals Incorporated, 275 Boulevard Armand Frappier, Laval, QC H7V 4A7, Canada
| | - Paul S. Charifson
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Anne-Laure Grillot
- Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| |
Collapse
|
6
|
Collier PN, Messersmith D, Le Tiran A, Bandarage UK, Boucher C, Come J, Cottrell KM, Damagnez V, Doran JD, Griffith JP, Khare-Pandit S, Krueger EB, Ledeboer MW, Ledford B, Liao Y, Mahajan S, Moody CS, Roday S, Wang T, Xu J, Aronov AM. Discovery of Highly Isoform Selective Thiazolopiperidine Inhibitors of Phosphoinositide 3-Kinase γ. J Med Chem 2015; 58:5684-8. [DOI: 10.1021/acs.jmedchem.5b00498] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Philip N. Collier
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - David Messersmith
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Arnaud Le Tiran
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Upul K. Bandarage
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Christina Boucher
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Jon Come
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Kevin M. Cottrell
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Veronique Damagnez
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - John D. Doran
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - James P. Griffith
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Suvarna Khare-Pandit
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Elaine B. Krueger
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Mark W. Ledeboer
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Brian Ledford
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Yusheng Liao
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Sudipta Mahajan
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Cameron S. Moody
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Setu Roday
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Tiansheng Wang
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Jinwang Xu
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | - Alex M. Aronov
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, Massachusetts 02210, United States
| |
Collapse
|
7
|
Grillot AL, Le Tiran A, Shannon D, Krueger E, Liao Y, O'Dowd H, Tang Q, Ronkin S, Wang T, Waal N, Li P, Lauffer D, Sizensky E, Tanoury J, Perola E, Grossman TH, Doyle T, Hanzelka B, Jones S, Dixit V, Ewing N, Liao S, Boucher B, Jacobs M, Bennani Y, Charifson PS. Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability. J Med Chem 2014; 57:8792-816. [PMID: 25317480 DOI: 10.1021/jm500563g] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Compound 3 is a potent aminobenzimidazole urea with broad-spectrum Gram-positive antibacterial activity resulting from dual inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in rodent models of bacterial infection. Preclinical in vitro and in vivo studies showed that compound 3 covalently labels liver proteins, presumably via formation of a reactive metabolite, and hence presented a potential safety liability. The urea moiety in compound 3 was identified as being potentially responsible for reactive metabolite formation, but its replacement resulted in loss of antibacterial activity and/or oral exposure due to poor physicochemical parameters. To identify second-generation aminobenzimidazole ureas devoid of reactive metabolite formation potential, we implemented a metabolic shift strategy, which focused on shifting metabolism away from the urea moiety by introducing metabolic soft spots elsewhere in the molecule. Aminobenzimidazole urea 34, identified through this strategy, exhibits similar antibacterial activity as that of 3 and did not label liver proteins in vivo, indicating reduced/no potential for reactive metabolite formation.
Collapse
Affiliation(s)
- Anne-Laure Grillot
- Vertex Pharmaceuticals Incorporated , 50 Northern Avenue, Boston, Massachusetts 02210, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|